SCHEMBL11025816

SCHEMBL11025816

COC(=O)c1ccc2c(c1)C(C)(C)CC(c1cc(F)cc(N3CCOCC3)c1)N2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKAG1 P54619 1/20 0.40
▸ PRKAA1 Q13131 1/20 0.40
▸ PRKAB1 Q9Y478 1/20 0.40
▸ ALOX15 P16050 4/20 0.39
▸ MRGPRX4 Q96LA9 1/20 0.38
▸ MAPT P10636 4/20 0.37
▸ F10 P00742 1/20 0.37
▸ F11 P03951 1/20 0.37
▸ F7 P08709 1/20 0.37
▸ NTRK1 P04629 1/20 0.36
▸ NTRK3 Q16288 1/20 0.36
▸ NTRK2 Q16620 1/20 0.36
▸ ALDH1A1 P00352 6/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42376 0.90 PRKAG1 (0.42) PRKAG1PRKAA1PRKAB1ALOX15MAPT
SCHEMBL11029216 0.89 PRKAG1 (0.41) PRKAG1PRKAA1PRKAB1ALOX15MAPT
SCHEMBL45124 0.89 PRKAG1 (0.52) PRKAG1PRKAA1PRKAB1MAPTALDH1A1
SCHEMBL45015 0.88 MAPT (0.40) PRKAG1PRKAA1PRKAB1MAPTNTRK1
SCHEMBL45781 0.88 F10 (0.45) ALOX15MRGPRX4MAPTF10F11
SCHEMBL11027687 0.86 PRKAG1 (0.38) PRKAG1PRKAA1PRKAB1ALOX15MAPT
SCHEMBL45014 0.86 HTR1A (0.39) PRKAG1PRKAA1PRKAB1MAPTNTRK1
SCHEMBL11940877 0.85 SCN9A (0.39) PRKAG1PRKAA1PRKAB1MAPTNTRK1
SCHEMBL45267 0.83 PRKAG1 (0.46) PRKAG1PRKAA1PRKAB1MAPTNTRK1
SCHEMBL47271 0.81 PRKAG1 (0.42) PRKAG1PRKAA1PRKAB1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809369-B2 Tetrahydroquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2014-08-19 — — US disclosed
EP-2668165-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2013-12-04 — — EP disclosed
WO-2012101068-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-08-02 — — WO disclosed
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES RAB1A, RABL3, RAB7A PRKAG1 2822/4885PRKAA1 2934/4885PRKAB1 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback